Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American ph...

He is heading a new company for the development of Coegin’s cancer drug

The biotechnology company Coegin Pharma places the development of its drug candidate AVX420 in a newly formed company, Avexxin Oncology, based in Norway, and Jo...

“An entire industry is about to be wiped out”

According to Jennie Ekbeck, CEO of Umeå Biotech Incubators, Sweden risks not having any small diagnostic companies left in five years.

Uppgifter: Sanofi tar in bud på konsumenthälsodivision

Den franska läkemedelsjätten Sanofi ska enligt uppgifter ha bett om initiala bud för sin konsumenthälsoverksamhet, som är värderad till runt 20 miljarder dollar.

Kompauto Nordic AB

Study: An objective diagnosis of constant tinnitus may be possible

A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tin...

Björn Ursing: Physicians new role in AI driven healthcare

”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians cha...

Specific proposals and targets top the universities’ desired priorities

What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...

MSD i storaffär – köper rättigheter till hjärt-kärlkandidat

Merck & Co, känt som MSD utanför USA och Kanada, har ingått ett exklusivt licensavtal med kinesiska Hengrui Pharma. Avtalet rör rättigheterna till läkemedelskan...

She creates pharmaceuticals on a 3D printer

The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a wel...

Bio-Works

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Exakt tryckreglering med Tescom – när precision är avgörande

OEM Automatic erbjuder ett brett sortiment av tryckregulatorer från Tescom – anpassade för att möta höga krav inom allt från gasleveranssystem till avancerad in...

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

The impact of the recession on the Swedish medtech sector

We need health care regardless of whether the economy is good or bad, but the current recession also affects the Medtech sector.

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Don't miss out on this unique opportunity

ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.

Pharma Outsourcing igång på Stockholm Waterfront

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

Paolo Macchiarini in court – “The sole intent was to cure”

Paolo Macchiarini’s surgical procedure was illegal, life-threatening and caused severe and prolonged suffering to patients the prosecution claimed when the tria...